Disclosed are methods of treating an aneurysm in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a SELP. Disclosed are methods of preventing rupture of an aneurysm comprising administering to a subject having an aneurysm a composition comprising a SELP, wherein the SELP is present in the aneurysm and prevents rupture. Also disclosed are methods of embolizing an aneurysm in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising SEEP. Disclosed are methods of treating AVM in a subject comprising administering to the subject a composition comprising a SELP. In some aspects, the SELP embolizes an abnormal blood vessel in the AVM. Disclosed are methods of embolizing an AVM in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a SELP, wherein the SELP embolizes an abnormal blood vessel in the AVM.

The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a polypeptide; viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.

The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a polypeptide; viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.

In order to develop tools and methods useful in a variety of applications, including the research and development of medical treatments which involve the modification of collagen protein and use of the same, the present invention provides a modified collagen protein expressed in a transformed cell and capable of forming collagen fibers outside of the cell, wherein the transformation is performed by introducing, into the cell, polynucleotides coding the modified collagen protein.

In order to develop tools and methods useful in a variety of applications, including the research and development of medical treatments which involve the modification of collagen protein and use of the same, the present invention provides a modified collagen protein expressed in a transformed cell and capable of forming collagen fibers outside of the cell, wherein the transformation is performed by introducing, into the cell, polynucleotides coding the modified collagen protein.

The present invention provides for devices and methods of treating wounds, including general wounds, gum disease and gingival tissues post scaling/root planning, using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm). Further disclosed are devices and methods capable of stimulating tissue regeneration at the site of a wound.

The invention concerns treating Tauopathies such as Alzheimer’s disease with a SCO- Spondin derived peptide administered through a systemic route to the patient. Said peptide has amino acid sequence X1-W-S-A1-W-S-A2-C-S-A3-A4-C-G-X2, in which A1, A2, A3 and A4 consists of amino acid sequences consisting of 1 to 5 amino acids, X1 and X2 consists of amino acid sequences consisting of 1 to 6 amino acids, or X1 and X2 are absent; it being possible for the N-terminal amino acid to be acetylated, for the C-terminal amino acid to be amidated, or the N-terminal amino acid to be acetylated and the C-terminal amino acid to be amidated.

An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The concentration of the macromolecular drug compound in the core is greater than the concentration of the macromolecular drug compound in the membrane layer.

An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The concentration of the macromolecular drug compound in the core is greater than the concentration of the macromolecular drug compound in the membrane layer.

An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The membrane polymer matrix contains a hydrophobic polymer in combination with a hydrophilic compound, and the weight ratio of the hydrophobic polymer to the hydrophilic compound within the membrane polymer matrix ranges from about 0.25 to about 200.